Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2026

Intangible Asset, Goodwill and Other [Abstract]

Intangible Assets — Intangible assets consisted of the following (dollars in thousands):


	Estimated		September 30, 2026							December 31, 2025
	Useful Life (Years)		Cost		Accumulated Amortization			Net Book Value		Cost		Accumulated Amortization			Net Book Value
Developed technology – Furoscix(1)		15.2		323,600		(17,723	)		305,877		194,000		(3,973	)		190,027
IPR&D - ReadyFlow Formulation(1)		—		—		—			—		129,600		—			129,600
iSPERSE License – IPR&D(2)		—		4,300		—			4,300		4,300		—			4,300
Developed technology – V-Go(2)		7.5		1,200		(573	)		627		1,200		(428	)		772
Total			$	329,100		(18,296	)	$	310,804	$	329,100	$	(4,401	)	$	324,699

(1)

The carrying amount of Developed technology – Furoscix as of September 30, 2026 includes both the on-body infusor and the ReadyFlow formulation which has been reclassified from IPR&D – Furoscix ReadyFlow to Developed technology – Furoscix on the consolidated balance sheets following the July 2026 FDA approval of the asset and the useful life was extended to December 31, 2040.

(2)

Included within Other intangible assets on the consolidated balance sheets.